US equities
|
MU
$1,097.39
▲+3.03%
NVDA
$230.86
▲+1.09%
SNDK
$1,787.69
▲+2.75%
INTC
$120.00
▼-0.19%
AAPL
$330.32
▼-0.81%
GOOGL
$338.24
▼-1.70%
TSLA
$354.11
▼-0.20%
AMD
$615.73
▲+0.65%
MU
$1,097.39
▲+3.03%
NVDA
$230.86
▲+1.09%
SNDK
$1,787.69
▲+2.75%
INTC
$120.00
▼-0.19%
AAPL
$330.32
▼-0.81%
GOOGL
$338.24
▼-1.70%
TSLA
$354.11
▼-0.20%
AMD
$615.73
▲+0.65%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Arcutis Biotherapeutics, Inc. - Common stock
(NQ:
ARQT
)
25.29
-1.14 (-4.31%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 1, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Arcutis Biotherapeutics, Inc. - Common stock
< Previous
1
2
3
4
5
Next >
Simone Biles Partners with Arcutis to Launch the Skin to Believe In Campaign, Raising Awareness of Seborrheic Dermatitis and Eczema, and Inspiring People to Explore Treatment Options
September 29, 2026
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis Announces Second Quarter 2026 Financial Results and Provides Business Update
August 05, 2026
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis Expands Board of Directors with Appointment of Chris Peetz
July 16, 2026
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Infants Down to 3 Months
July 08, 2026
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis Launches New Virtual Health Platform Supporting Access to Care for Individuals Living with Chronic Inflammatory Skin Diseases, Including Approved ZORYVE® (roflumilast) Indications
June 30, 2026
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children as Young as Age 2
June 29, 2026
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
New Expert Consensus Provides Age-Specific Guidance for Improving Care for Individuals with Genital Psoriasis Published in the American Journal of Clinical Dermatology
June 03, 2026
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis Announces First Quarter 2026 Financial Results and Provides Business Update
May 06, 2026
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis Submits Supplemental New Drug Application to the FDA for ZORYVE® (roflumilast) Cream 0.05% to Expand Indication for Treatment of Atopic Dermatitis to Infants Down to 3 Months
April 27, 2026
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis’ ZORYVE® (roflumilast) Cream Receives Strong Recommendation in American Academy of Dermatology First-Ever Pediatric Atopic Dermatitis Guidelines
April 22, 2026
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Palvella Therapeutics Appoints Accomplished Commercial Leader Kent Taylor as Senior Vice President of Sales
April 07, 2026
From
Palvella Therapeutics Inc.
Via
GlobeNewswire
Arcutis Presents New Phase 2 Results in Infants with Atopic Dermatitis in Late-Breaking Session Today at the 2026 American Academy of Dermatology Annual Meeting
March 28, 2026
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis to Present New Clinical Data in a Late-Breaking Podium Presentation and Scientific Posters at the 2026 American Academy of Dermatology Annual Meeting
March 18, 2026
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data with ZORYVE® (roflumilast) Cream 0.05% for Treatment of Mild-to-Moderate Atopic Dermatitis in Children Ages 2–5 in Pediatric Dermatology
March 10, 2026
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis Announces Promotion of Mas Matsuda to Executive Vice President and Chief Legal Officer to Support Next Phase of Growth
March 05, 2026
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis Begins Enrolling Phase 1a/1b Study Evaluating ARQ-234, a CD200R Agonist, in Healthy Volunteers and Adults With Atopic Dermatitis
March 03, 2026
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
February 25, 2026
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Professional Golfer Max Homa Joins Arcutis’ Free to Be Me Campaign, Urging Individuals with Seborrheic Dermatitis to Tee Up a Conversation with Their Healthcare Provider About Long-Term Treatments
February 24, 2026
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis Announces Positive Topline Results for INTEGUMENT-INFANT Phase 2 Trial of ZORYVE® (roflumilast) Cream 0.05% in Infants with Mild to Moderate Atopic Dermatitis
February 02, 2026
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis Biotherapeutics, Inc. Announces Termination of Promotion Agreement with Kowa
January 26, 2026
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Nationwide Survey Underscores Concerns with Use of Topical Steroids and Need for Long-Term Treatment Strategies Facing the 46 Million Americans with Chronic Inflammatory Skin Conditions
January 21, 2026
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis Highlights 2026 Strategic Priorities and Anticipated Milestones
January 12, 2026
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children Ages 2 to 5
November 17, 2025
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis Completes Enrollment in INTEGUMENT-INFANT Phase 2 Study Evaluating ZORYVE® (roflumilast) Cream 0.05% in Infants with Atopic Dermatitis
November 13, 2025
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data of ZORYVE® (roflumilast) Foam 0.3% in Individuals with Seborrheic Dermatitis in American Journal of Clinical Dermatology
November 04, 2025
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis Launches ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Children Ages 2 to 5
October 30, 2025
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Mother-Daughter Duo, Tori Spelling and Stella McDermott, Partner With Arcutis Biotherapeutics in the Free to Be Me Campaign, Urging People With Inflammatory Skin Conditions to Speak With Their Healthcare Provider About Long-Term Treatments
October 30, 2025
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis Outlines Strategy for Driving Sustainable Growth and Announces Third Quarter 2025 Financial Results
October 28, 2025
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis to Present New Quality of Life and Long-Term Data with ZORYVE® (roflumilast) Cream 0.15% and 0.05% for the Treatment of Atopic Dermatitis at the Fall Clinical Dermatology Conference
October 24, 2025
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5
October 06, 2025
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
Next >
